Rocket Pharmaceuticals, Inc.
HealthcareNASDAQ:RCKT · NASDAQ Global Market
+$0.09 today
Vol 2.42M · Avg 3.13M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-80.5%
avg -49.6%
ROIC
-75.4%
avg -37.8%
ROA
-67.5%
avg -39.4%
Analysis
ROA is currently the strongest return metric at -67.5% versus its period average of -39.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Gaurav D. Shah | Chief Executive Officer & Director | $1.09M | — | 51 | $1.06M | 0.97% |
Martin Louis Wilson | Gen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corporation Officer | $767,467.00 | — | 50 | $677,977.00 | 0.62% |
Jonathan Schwartz | Chief Science & Gene Therapy Officer | $614,334.00 | — | 61 | $299,064.00 | 0.27% |
Christopher Stevens | Chief Operating Officer | $604,469.00 | — | 45 | $469,129.00 | 0.43% |
John C. Militello | VP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | $425,611.00 | — | 53 | $0.00 | <0.01% |
Sarbani Chaudhuri | Chief Commercial & Medical Affairs Officer | — | — | 51 | $267,510.00 | 0.24% |
Kevin Giordano | Director of Corporate Communications | — | — | — | — | — |
Syed Ali-Aamir Rizvi | Chief Medical Officer | — | — | 59 | $407,874.00 | 0.37% |
Meg Dodge | Senior Vice President & Head of External Affairs | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$68,500.00
Sells
32
$657,514.64
Net Sentiment
$589,014.64
Net selling
Most Active
Militello John
12 transactions
1–10 of 34
Analysis
Insiders reported 2 buys worth $68,500.00 and 32 sells worth $657,514.64 over the last 12 months. That adds up to net selling of $589,014.64. Militello John was the most active insider with 12 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$814.99M
Design Therapeutics, Inc.
NASDAQ:DSGN
$685.15M
Annexon, Inc.
NASDAQ:ANNX
$563.29M
Solid Biosciences Inc.
NASDAQ:SLDB
$556.28M
DBV Technologies S.A.
NASDAQ:DBVT
$416.60M
Autolus Therapeutics plc
NASDAQ:AUTL
$415.18M
Aura Biosciences, Inc.
NASDAQ:AURA
$411.52M
I-Mab
IMAB
$235.66M
Quantum-Si incorporated
NASDAQ:QSI
$187.28M
Galectin Therapeutics Inc.
NASDAQ:GALT
$175.84M
Who manages RCKT?
Rocket Pharmaceuticals, Inc. (RCKT) lists 9 active executives. The top listed executive is John C. Militello, VP of Finance, Senior Controller & Treasurer and Principal Accounting Officer.
Are RCKT insiders buying or selling?
Recent insider activity shows net buying of $56.11M.
Explore More
Continue the stock analysis
Jump to another research area for this company.